Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Gottesman Website

Michael M. Gottesman, M.D.

Selected Publications

1)  Fung KL, Pan J, Ohnuma S, Lund PE, Pixley JN, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.
Cancer Res. 74: 598-608, 2014.
2)  Lavi O, Greene JM, Levy D, Gottesman MM.
Simplifying the complexity of resistance heterogeneity in metastasis.
Trends Mol Med. 20: 129-136, 2014.
3)  Greene J, Lavi O, Gottesman MM, Levy D.
The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
Bull. Math. Biol. 76: 627-53, 2014.
4)  Bakhsheshian J, Wei BR, Chang KE, Shukla S, Ambudkar SV, Simpson RM, Gottesman MM, Hall MD.
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Proc. Natl. Acad. Sci. U.S.A. 110: 20801-6, 2013.
5)  Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM.
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.
Exp. Cell Res. 319: 566-74, 2013.
6)  Kannan P, Pike VW, Halldin C, Langer O, Gottesman MM, Innis RB, Hall MD.
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.
Mol. Pharm. 10: 2222-9, 2013.
7)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. [Epub ahead of print], 2013.
8)  Jaeger AA, Das CK, Morgan NY, Pursley RH, McQueen PG, Hall MD, Pohida TJ, Gottesman MM.
Microfabricated polymeric vessel mimetics for 3-D cancer cell culture.
Biomaterials. 34: 8301-13, 2013.
9)  Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, Sjöberg J, Viktorsson K, Lewensohn R, Landgren O, Gottesman MM, Gillet JP.
Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity.
Cancer. 2013.
10)  Xue X, Hall MD, Zhang Q, Wang PC, Gottesman MM, Liang XJ.
Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking.
ACS Nano. 2013.
11)  Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM.
Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2.
Drug Metab. Dispos. 2013.
12)  Galski H, Oved-Gelber T, Simanovsky M, Lazarovici P, Gottesman MM, Nagler A.
P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.
Biochem. Pharmacol. 2013.
13)  Salari R, Kimchi-Sarfaty C, Gottesman MM, Przytycka TM.
Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies.
Nucleic Acids Res. 41: 44-53, 2013.
14)  Gillet JP, Varma S, Gottesman MM.
The clinical relevance of cancer cell lines.
J. Natl. Cancer Inst. 105: 452-8, 2013.
15)  Lavi O, Greene JM, Levy D, Gottesman MM.
The Role of Cell Density and Intratumoral Heterogeneity in Multidrug Resistance.
Cancer Res. 2013.
16)  Gottesman MM.
The role of the NIH in nurturing clinician-scientists.
N. Engl. J. Med. 368: 2249-51, 2013.
17)  Hochman J, Shen D, Gottesman MM, Chan C.
Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye.
Clin. Exp. Metastasis. [Epub ahead of print], 2012.
18)  Shen DW, Pouliot LM, Hall MD, Gottesman MM.
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.
Pharmacol. Rev. 64: 706-21, 2012.
19)  Pouliot LM, Chen Y, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD.
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.
Cancer Res. [Epub ahead of print], 2012.
20)  Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM.
Collateral sensitivity as a strategy against cancer multidrug resistance.
Drug Resist. Updat. 15: 98-105, 2012.
21)  Shaffer BC, Gillet J, Patel C, Baer MR, Bates SE, Gottesman MM.
Drug resistance: Still a daunting challenge to the successful treatment of AML.
Drug Resist. Updat. 15: 62-69, 2012.
22)  Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P.
Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors.
Cancer Res. 72: 2350-61, 2012.
23)  Gillet J, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat A, Sood AK, Ambudkar SV, Seiden M, Rueda BR, Gottesman MM.
Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients With Primary Ovarian Serous Carcinoma.
Clinical Cancer Res. 18: 3197-3206, 2012.
24)  Gillet J, Gottesman MM.
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
Drug Resist. Updat. 15: 2-4, 2012.
25)  Shen DW, Gottesman MM.
RAB8 enhances TMEM205-mediated cisplatin resistance.
Pharm. Res. 29: 643-50, 2012.
26)  Padmanabhan R, Chen KG, Gillet JP, Handley M, Mallon BS, Hamilton RS, Park K, Varma S, Mehaffey MG, Robey PG, McKay RD, Gottesman MM.
Regulation and Expression of the ATP-Binding Cassette Transporter ABCG2 in Human Embryonic Stem Cells.
Stem Cells. 30: 2175-87, 2012.
27)  Kimchi-Sarfaty C, Gottesman MM.
SV40 In Vitro Packaging: A Pseudovirion Gene Delivery System.
Cold Spring Harb Protoc. 2012, 2012.
28)  Lavi O, Gottesman MM, Levy D.
The dynamics of drug resistance: A mathematical perspective.
Drug Resist. Updat. 15: 90-7, 2012.
29)  Shen D, Pouliot LM, Gillet J, Ma W, Johnson AC, Hall MD, Gottesman MM.
The Transcription Factor GCF2 Is an Upstream Repressor of the Small GTPAse RhoA, Regulating Membrane Protein Trafficking, Sensitivity to Doxorubicin, and Resistance to Cisplatin.
Mol Pharm. [Epub ahead of print], 2012.
30)  Gillet JP, Gottesman MM.
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer.
Curr Pharm Biotechnol. 12: 686-92, 2011.
31)  Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM.
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.
Mol. Pharm. 8: 2080-8, 2011.
32)  Goldsborough AS, Handley MD, Dulcey AE, Pluchino KM, Kannan P, Brimacombe KR, Hall MD, Griffiths G, Gottesman MM.
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
J. Med. Chem. 54: 4987-97, 2011.
33)  Lucia MB, Anu R, Handley M, Gillet JP, Wu CP, De Donatis GM, Cauda R, Gottesman MM.
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Br. J. Cancer. 105: 513-22, 2011.
34)  Macadangdang B, Zhang N, Lund PE, Marple AH, Okabe M, Gottesman MM, Appella DH, Kimchi-Sarfaty C.
Inhibition of Multidrug Resistance by SV40 Pseudovirion Delivery of an Antigene Peptide Nucleic Acid (PNA) in Cultured Cells.
PLoS ONE. 6: e17981, 2011.
35)  Kannan P, Brimacombe KR, Kreisl WC, Liow JS, Zoghbi SS, Telu S, Zhang Y, Pike VW, Halldin C, Gottesman MM, Innis RB, Hall MD.
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Proc. Natl. Acad. Sci. U.S.A. 108: 2593-8, 2011.
36)  Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108: 18708-13, 2011.
37)  Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, Gottesman MM, Bauer B, Thomas CJ, Ambudkar SV.
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters.
Mol. Pharm. 8: 1292-302, 2011.
38)  Hall MD, Brimacombe KR, Varonka MS, Pluchino KM, Monda JK, Li J, Walsh MJ, Boxer MB, Warren TH, Fales HM, Gottesman MM.
Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.
J. Med. Chem. 54: 5878-89, 2011.
39)  Garcia-Perez A, Wyatt RG, Gottesman MM.
Changes in NIH criteria for tenure to reward clinical/translational teams.
Clin Transl Sci. 3: 4-5, 2010.
40)  Gottesman MM, Jaffe HB.
Commentary: A delicate balance: weighing the effects of conflict-of-interest rules on intramural research at the National Institutes of Health.
Acad Med. 85: 1660-2, 2010.
41)  Shen D, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM.
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.
J Cell Physiol. 225: 822-8, 2010.
42)  Gillet JP, Gottesman MM.
Mechanisms of multidrug resistance in cancer.
Methods Mol. Biol. 596: 47-76, 2010.
43)  Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L.
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.
Proc. Natl. Acad. Sci. U.S.A. 107: 7449-54, 2010.
44)  Kannan P, Brimacombe KR, Zoghbi SS, Liow JS, Morse C, Taku AK, Pike VW, Halldin C, Innis RB, Gottesman MM, Hall MD.
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
Drug Metab. Dispos. 38: 917-22, 2010.
45)  Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
J. Natl. Cancer Inst. 102: 1637-52, 2010.
46)  Lund PE, Hunt RC, Gottesman MM, Kimchi-Sarfaty C.
Pseudovirions as vehicles for the delivery of siRNA.
Pharm. Res. 27: 400-20, 2010.
47)  Gillet J, Okabe M, Gottesman M.
Arias I, Fausto N, Boyer J, Chisari F, Shafritz D, eds.
The Hepatocyte and the Cancer Cell: Dr. Jekyll and Mr. Hyde. In: The liver: Biology and Pathobiology, 5th Edition.
Oxford, England: Wiley-Blackwell; 2009. p. 1075-1090 [Book Chapter]
48)  Brimacombe KR, Hall MD, Auld DS, Inglese J, Austin CP, Gottesman MM, Fung K.
A Dual-Fluorescence High-Throughput Cell Line System for Probing Multidrug Resistance.
Assay Drug Dev Technol. 7: 233-49, 2009.
49)  Fung KL, Gottesman MM.
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.
Biochim. Biophys. Acta. 1794: 860-71, 2009.
50)  Wang PC, Blumenthal RP, Zhao Y, Schneider JA, Miller N, Grodzinski P, Gottesman MM, Tinkle S, Wang K, Wang C, Liang X.
Building Scientific Progress without Borders: Nanobiology and Nanomedicine in China and the U.S.
Cancer Res. 69: 5294-5, 2009.
51)  Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, Eichler G, Weinstein JN, Pommier Y, Ambudkar SV, Gottesman MM, Gillet JP.
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.
Mol. Cancer Ther. 8: 2057-66, 2009.
52)  Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G.
Identification of compounds selectively killing multidrug-resistant cancer cells.
Cancer Res. 69: 8293-301, 2009.
53)  Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD.
Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications.
Clin. Pharmacol. Ther. 86: 368-77, 2009.
54)  Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, Vieira WD, Hearing VJ, Gottesman MM.
Influence of melanosome dynamics on melanoma drug sensitivity.
J. Natl. Cancer Inst. 101: 1259-71, 2009.
55)  Chen KG, Valencia JC, Gillet J, Hearing VJ, Gottesman MM.
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma.
Pigment Cell Melanoma Res. 22: 740-9, 2009.
56)  Hall MD, Handley MD, Gottesman MM.
Is resistance useless? Multidrug resistance and collateral sensitivity.
Trends Pharmacol. Sci. 30: 546-56, 2009.
57)  Hunt R, Sauna ZE, Ambudkar SV, Gottesman MM, Kimchi-Sarfaty C.
Silent (Synonymous) SNPs: Should We Care About Them?.
Methods Mol. Biol. 578: 23-39, 2009.
58)  Gottesman MM, Ambudkar SV, Xia D.
Structure of a multidrug transporter.
Nat. Biotechnol. 27: 546-7, 2009.
59)  Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM.
Synthesis, Activity, and Pharmacophore Development for Isatin-beta-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells.
J. Med. Chem. 52: 3191-204, 2009.
60)  Gillet JP, Macadangdang B, Fathke RL, Gottesman MM, Kimchi-Sarfaty C.
The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer.
Methods Mol. Biol. 542: 5-54, 2009.
61)  Okabe M, Szakács G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM.
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
Mol. Cancer Ther. 7: 3081-91, 2008.
62)  Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, Gottesman MM.
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.
Mol. Cancer Res. 6: 1499-506, 2008.
63)  Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R.
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima.
J. Mol. Biol. 383: 281-91, 2008.
64)  Kimchi-Sarfaty C, Oh JM, Kim I, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM.
A "silent" polymorphism in the MDR1 gene changes substrate specificity.
Science. 315: 525-8, 2007.
65)  Gillet J, Kimchi-Sarfaty C, Shinar S, Licht T, Lee C, Hafkemeyer P, Hrycyna C, Pastan I, Gottesman M.
Templeton N, eds.
Selectable Markers for Gene Therapy. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition.
Boca Raton, Florida: Taylor and Francis; 2008. p. 555-580 [Book Chapter]
66)  Liang XJ, Yin JJ, Taylor B, Winkovitch SM, Garfield SH, Shen DW, Gottesman MM, Aszalos A.
Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines.
Cancer Chemother. Pharmacol. 2008.
67)  Elbaz B, Alperovitch A, Gottesman MM, Kimchi-Sarfaty C, Rahamimoff H.
Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific.
Mol. Pharmacol. 73: 1254-63, 2008.
68)  Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM.
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.
Annu. Rev. Pharmacol. Toxicol. 48: 495-535, 2008.
69)  Marple A, Gottesman M, Kimchi-Sarfaty C.
Hefferon K, eds.
Efficient gene therapy delivery by SV40-derived vectors. In: Virus Expression Vectors.
Trivandrum, India: Transworld Research Network; 2007. p. 247-265 [Book Chapter]
70)  Rahamimoff H, Elbaz B, Alperovich A, Kimchi-Sarfaty C, Gottesman MM, Lichtenstein Y, Eskin-Shwartz M, Kasir J.
Cyclosporin A-dependent downregulation of the Na+/Ca2+ exchanger expression.
Ann. N. Y. Acad. Sci. 1099: 204-14, 2007.
71)  Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, Kim IW, Jones A, Arora M, Gribar J, Gurwitz D, Gottesman MM.
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.
Pharmacogenomics. 8: 29-39, 2007.
72)  Wu CP, Shukla S, Calcagno AM, Hall MD, Gottesman MM, Ambudkar SV.
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
Mol. Cancer Ther. 6: 3287-96, 2007.
73)  Paterson JK, Shukla S, Black CM, Tachiwada T, Garfield S, Wincovitch S, Ernst DN, Agadir A, Li X, Ambudkar SV, Szakacs G, Akiyama SI, Gottesman MM.
Human ABCB6 Localizes to Both the Outer Mitochondrial Membrane and the Plasma Membrane.
Biochemistry. 2007.
74)  Paterson JK, Gottesman MM.
P-Glycoprotein is not present in mitochondrial membranes.
Exp. Cell Res. 313: 3100-5, 2007.
75)  Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.
Cancer Res. 67: 9609-12, 2007.
76)  Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM.
The sounds of silence: synonymous mutations affect function.
Pharmacogenomics. 8: 527-532, 2007.
77)  Chen KG, Gottesman MM.
Hearing VJ, Leong SP, eds.
How melanoma cells evade chemotherapy: role of transporter-dependent and independent resistance mechanisms. In: From Melanocytes to Malignant Melanoma.
Totowa, New Jersey: Humana Press; 2006. p. 591-603 [Book Chapter]
78)  Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV.
Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery.
Mol. Pharm. 3: 87-93, 2006.
79)  Gottesman MM, Ludwig J, Xia D, Szakács G.
Defeating drug resistance in cancer.
Discovery medicine. 6: 18-23, 2006.
80)  Liang XJ, Mukherjee S, Shen DW, Maxfield FR, Gottesman MM.
Endocytic recycling compartments altered in cisplatin-resistant cancer cells.
Cancer Res. 66: 2346-53, 2006.
81)  Shen DW, Liang XJ, Suzuki T, Gottesman MM.
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.
Mol. Pharmacol. 69: 1383-8, 2006.
82)  Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M.
International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future.
Ocul. Immunol. Inflamm. 14: 139-44, 2006.
83)  Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD, Hearing VJ, Gottesman MM.
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas.
Proc. Natl. Acad. Sci. U.S.A. 103: 9903-7, 2006.
84)  Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM.
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Cancer Res. 66: 4808-15, 2006.
85)  Kimchi-Sarfaty C, Vieira WD, Dodds D, Sherman A, Kreitman RJ, Shinar S, Gottesman MM.
SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.
Cancer Gene Ther. 13: 648-57, 2006.
86)  Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.
Targeting multidrug resistance in cancer.
Nature reviews. Drug discovery. 5: 219-34, 2006.
87)  Gottesman MM, Ling V.
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research.
FEBS Lett. 580: 998-1009, 2006.
88)  Ambudkar SV, Sauna ZE, Gottesman MM, Szakacs G.
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1).
Trends Pharmacol. Sci. 26: 385-7, 2005.
89)  Liang XJ, Taylor B, Cardarelli C, Yin JJ, Annereau JP, Garfield S, Wincovitch S, Szakács G, Gottesman MM, Aszalos A.
Different roles for K+ channels in cisplatin-resistant cell lines argue against a critical role for these channels in cisplatin resistance.
Anticancer Res. 25: 4113-22, 2005.
90)  Kimchi-Sarfaty C, Brittain S, Garfield S, Caplen NJ, Tang Q, Gottesman MM.
Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.
Hum. Gene Ther. 16: 1110-5, 2005.
91)  Bar-Sinai A, Bassa N, Fischette M, Gottesman MM, Love DC, Hanover JA, Hochman J.
Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer.
Cancer Res. 65: 7223-30, 2005.
92)  Chen KG, Szakács G, Annereau JP, Rouzaud F, Liang XJ, Valencia JC, Nagineni CN, Hooks JJ, Hearing VJ, Gottesman MM.
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes.
Pigment Cell Res. 18: 102-12, 2005.
93)  Liang XJ, Shen DW, Chen KG, Wincovitch SM, Garfield SH, Gottesman MM.
Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.
J Cell Physiol. 202: 635-41, 2005.
94)  Tarasova NI, Seth R, Tarasov SG, Kosakowska-Cholody T, Hrycyna CA, Gottesman MM, Michejda CJ.
Transmembrane Inhibitors of P-Glycoprotein, an ABC Transporter.
J Med Chem. 48: 3768-75, 2005.
95)  Chen KG, Gottesman MM.
Useful tool to generate unidirectional deletion vectors by utilizing the star activity of BamHI in an NcoI-BamHI-XhoI cassette.
Biotechniques. 38: 198, 200, 202, 204, 2005.
96)  Gottesman M, Licht T, Kimchi-Sarfaty C, Zhou Y, Lee C, Shoshani T, Hafkemeyer P, Hrycyna C, Pastan I.
Lasic D, Templeton N, eds.
Selectable markers for gene therapy. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 2nd Ed.
New York: Marcel Dekker, Inc.; 2004. p. 391-412 [Book Chapter]
97)  Liang XJ, Shen DW, Gottesman MM.
A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.
J. Inorg. Biochem. 98: 1599-606, 2004.
98)  Pétriz J, Gottesman MM, Aran JM.
An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein.
Current drug delivery. 1: 43-56, 2004.
99)  Annereau JP, Szakács G, Tucker CJ, Arciello A, Cardarelli C, Collins J, Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS, Gottesman MM.
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
Mol. Pharmacol. 66: 1397-405, 2004.
100)  Liang XJ, Yin JJ, Zhou JW, Wang PC, Taylor B, Cardarelli C, Kozar M, Forte R, Aszalos A, Gottesman MM.
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
Exp. Cell Res. 293: 283-91, 2004.
101)  Szakács G, Gottesman MM.
Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.
Molecular interventions. 4: 323-5, 2004.
102)  Liang XJ, Shen DW, Gottesman MM.
Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells.
Mol. Pharmacol. 65: 1217-24, 2004.
103)  Shen DW, Liang XJ, Gawinowicz MA, Gottesman MM.
Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines.
Mol. Pharmacol. 66: 789-93, 2004.
104)  Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC.
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.
Mol. Cancer Ther. 3: 633-9, 2004.
105)  Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM.
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.
Cancer Cell. 6: 129-37, 2004.
106)  Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM.
Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells.
Br. J. Cancer. 91: 270-6, 2004.
107)  Kimchi-Sarfaty C, Gottesman MM.
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy.
Current pharmaceutical biotechnology. 5: 451-8, 2004.
108)  Szakács G, Chen GK, Gottesman MM.
The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.
Cancer Biol. Ther. 3: 382-4, 2004.
109)  Kimchi-Sarfaty C, Alexander NS, Brittain S, Ali S, Gottesman MM.
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.
BioTechniques. 37: 270-5, 2004.
110)  Gottesman MM.
Cancer gene therapy: an awkward adolescence.
Cancer Gene Ther. 10: 501-8, 2003.
111)  Ying YL, Shen DW, Liang XJ, Gottesman MM.
Codominance of cisplatin resistance in somatic cell hybrids.
J. Cell. Physiol. 196: 63-9, 2003.
112)  Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, Nishizuka S, Szakacs G, Annereau JP, Shankavaram U, Lababidi S, Smith LH, Gottesman MM, Weinstein JN.
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells.
Genome Biol. 4: R82, 2003.
113)  Sugimoto Y, Tsukahara S, Sato S, Suzuki M, Nunoi H, Malech HL, Gottesman MM, Tsuruo T.
Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
The journal of gene medicine. 5: 366-76, 2003.
114)  Kimchi-Sarfaty C, Arora M, Sandalon Z, Oppenheim A, Gottesman MM.
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.
Hum. Gene Ther. 14: 167-77, 2003.
115)  Stein WD, Robey R, Cardarelli C, Gottesman MM, Bates SE.
Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrest.
Cell Cycle. 2: 134-42, 2003.
116)  Liang XJ, Shen DW, Garfield S, Gottesman MM.
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.
Cancer Res. 63: 5909-16, 2003.
117)  Lelong-Rebel IH, Rebel G, Cardarelli CO, Pastan I, Gottesman MM.
Modulation by the ATP/GTP ratio of the phosphorylation level of P-glycoprotein and of various plasma membrane proteins of KB-V1 multidrug resistant cells.
Anticancer Res. 23: 2363-75, 2003.
118)  Alemán C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A, Gottesman MM.
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
Cancer Res. 63: 3084-91, 2003.
119)  Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM.
P-glycoprotein: from genomics to mechanism.
Oncogene. 22: 7468-85, 2003.
120)  Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, Gottesman MM.
Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines.
Br. J. Cancer. 88: 1327-34, 2003.
121)  Golin J, Ambudkar SV, Gottesman MM, Habib AD, Sczepanski J, Ziccardi W, May L.
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux.
J. Biol. Chem. 278: 5963-9, 2003.
122)  Licht T, Haskins M, Henthorn P, Kleiman SE, Bodine DM, Whitwam T, Puck JM, Gottesman MM, Melniczek JR.
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.
Proc. Natl. Acad. Sci. U.S.A. 99: 3123-8, 2002.
123)  Kimchi-Sarfaty C, Gribar JJ, Gottesman MM.
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system.
Mol. Pharmacol. 62: 1-6, 2002.
124)  Kimchi-Sarfaty C, Ben-Nun-Shaul O, Rund D, Oppenheim A, Gottesman MM.
In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.
Hum. Gene Ther. 13: 299-310, 2002.
125)  Gottesman MM.
Mechanisms of cancer drug resistance.
Annu. Rev. Med. 53: 615-27, 2002.
126)  Gottesman MM, Fojo T, Bates SE.
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat. Rev. Cancer. 2: 48-58, 2002.
127)  Lee CG, Vieira WD, Pastan I, Gottesman MM.
An episomally maintained MDR1 gene for gene therapy.
Hum. Gene Ther. 12: 945-53, 2001.
128)  Gottesman MM, Ambudkar SV.
Overview: ABC transporters and human disease.
J. Bioenerg. Biomembr. 33: 453-8, 2001.
129)  Ambudkar SV, Rosen BP, Gottesman MM.
Workshop on ABC Transporters and Human Diseases.
Drug Resist Updat. 3: 51-54, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/1/2014.